In a recent ruling, the Supreme Court has rejected a challenge concerning Medicare's drug price negotiation policies.
This decision may pose additional challenges for pharmaceutical companies that are pursuing related lawsuits.
The implications of this ruling could significantly affect the landscape of drug pricing and negotiations moving forward.